Phosphorus Attached Directly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 546/21)
  • Patent number: 10759795
    Abstract: The invention described herein pertains to four series of aza-A-ring indenoisoquinolines, which are inhibitors of topoisomerase IB (Top1), and the processes for preparing said aza-A-ring indenoisoquinolines. Also described are methods for treating cancer in mammals using the described aza-A-ring indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: September 1, 2020
    Assignees: PURDUE RESEARCH FOUNDATION, UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Mark S. Cushman, Daniel E. Beck, Yves Pommier
  • Patent number: 10363261
    Abstract: Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: July 30, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Florian Muller, David S. Maxwell, William G. Bornmann, Yu-Hsi Lin, Basvoju A. Bhanu Prasad, Zhenghong Peng, Duoli Sun, Nikunj Satani, M. Emilia Di Francesco, Ronald A. Depinho, Barbara Czako, Federica Pisaneschi
  • Patent number: 10174202
    Abstract: Compounds of formula I are disclosed: wherein X1, X2, X3, X4 are independently H, F, Cl, Br, I, CN, NO2, OR1, SR1, NR1R2, COR1, COOR1, CONR1R2, PO3R1R2, SO2R1, SO3R1 or R3; R1 and R2 are, e.g., H, alkyl or aryl or optionally a ring; R3 is, e.g., alkyl, alkenyl, alkynyl, aryl or cycloalkyl; Y is OR1, NR1R2, or NR1R3; Q is O, S, SO2, NR, C(R3)2, Si(R3)2, Ge(R3)2, P(?O)R3 or P(?O)OR3; Q and X1 can optionally form part of a ring; L and M are independently OR1, SR1, NR1R2 and R3; L and M can optionally form part of a ring; Z is O, S, NR1, CR1R3 or aryl; and Z and X4 can optionally form part of a ring.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: January 8, 2019
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E. V.
    Inventors: Maksim Sednev, Alexey Butkevich, Heydar Shojaei, Vladimir Belov, Stefan Hell, Christian Wurm, Dirk Kamin
  • Patent number: 10072035
    Abstract: The present invention relates to a novel phenanthroline phosphonic acid compound and a pharmaceutical salt thereof, as well as an application of the compound and the pharmaceutical salt thereof as collagen prolyl hydroxylase inhibitors in the preparation of drugs for preventing or treating collagen prolyl-4-hydroxylase related disease.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 11, 2018
    Assignee: GUANGZHOU BERYL THERAPEUTICS, INC
    Inventors: Yue Zhu, Yuzhen Liao, Li Zhang, Xu Bai
  • Patent number: 9206268
    Abstract: Methods and compositions are provided for inhibiting the polymerization of a vinyl aromatic monomer, such as styrene monomer, during elevated temperature processing or distillation thereof. The compositions comprise an inhibitor combination of (A) a hydroxylamine and (B) a stable free radical plus a retarder that is either; (C) dinitrobutylphenol or (D) quinone methide. The ratio of (A) to (B) ranges from about 5% (A) to 95% (B) to about 95% (A) to about 5% (B). The compositions are added to the vinyl aromatic monomer in amounts sufficient to prevent polymerization during the distillation process. Typically the inhibitor combination is added to the vinyl aromatic monomer in an amount ranging from about 10 to 150 ppm of the monomer. Retarders are typically added in an amount ranging from 50 to 1500 ppm of the vinyl aromatic monomer.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: December 8, 2015
    Assignee: General Electric Company
    Inventors: John Link, Mike Hong
  • Publication number: 20150119365
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Patent number: 9012639
    Abstract: The invention relates to copper(I) complexes of the formula A wherein X=Cl, Br or I (independently of one another); N*?E=a bidentate ligand, wherein E=a phosphinyl group including a phosphorus atom or an arsenyl group including an arsenic atom, wherein the phosphinyl group or the arsenyl group is combined with R in the form of R2E (where R=alkyl, aryl, alkoxy, or phenoxy; N*=imine function which is part of an aromatic group selected from pyridyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl and imidazolyl, the aromatic group optionally having at least one substituent to increase the solubility of the copper(I) complex in an organic solvent; and ?=at least one carbon atom which is likewise part of the aromatic group. The carbon atom is located directly adjacent both to the imine nitrogen atom, coordinating to Cu in the case of a bridging ligand and to the phosphorus or arsenic atom.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: April 21, 2015
    Assignee: Cynora GmbH
    Inventors: Hartmut Yersin, Uwe Monkowius, Tobias Fisher, Thomas Hofbeck, Thomas Baumann, Tobias Grab
  • Publication number: 20150053901
    Abstract: [Problem] To provide a fluorine-containing phosphate ester-amide which has high flame retardancy such as exhibiting flame retardant effects at a small quantity of addition, and sufficient hydrolysis resistance. [Solution] A fluorine-containing phosphate ester-amide represented by general formula (1). (In the formula, R1 and R2 are the same or different and represent a branched or linear alkyl group having 1 to 20 carbon atoms in which at least one carbon bonded to a nitrogen atom is a secondary or tertiary carbon, wherein R1 and R2 may have a substituent group selected from the group consisting of an alkoxy group, a hydroxy group, an amino group, a methyl amino group, an ethyl amino group, a dimethyl amino group, diethyl amino group and a fluorine atom. In addition, R1 and R2 may be bonded together to form a five- to eight-membered cyclic structure. X and Y are the same or different and represent a hydrogen atom or a fluorine atom, and n and m represent an integer of 1 to 6.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 26, 2015
    Applicant: TOSOH F- TECH, INC.
    Inventors: Hideyuki Mimura, Hiroaki Fujita, Hisao Eguchi
  • Publication number: 20140349368
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: February 17, 2014
    Publication date: November 27, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Donald W. Landry, Yuli Xie, Yidong Lu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Publication number: 20140311575
    Abstract: The present invention relates to modified surfaces. The surfaces comprise an inorganic material on which a phosphinic acid derivative is adsorbed. The phosphinic acid thus turns out to be a new anchoring group useful for surface derivatisation. The invention has many applications for photoelectric conversion devices, batteries, capacitors, electrochromic displays, chemical sensors, biological sensors, light emitting diodes, electrodes, semiconductors, separation membranes, selective adsorbents, adsorbents for HPLC, catalysts, implants, nanoparticles, antiadhesives, and anticorrosion coatings, for example.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventors: Shaik Mohammad Zakeeruddin, Peter Pechy, Michael Graetzel
  • Publication number: 20140309191
    Abstract: In part, the present invention is directed to antibacterial compounds and salts thereof.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 16, 2014
    Applicant: Affinium Pharmaceuticals, Inc.
    Inventors: Henry Pauls, Jailall Ramnauth
  • Patent number: 8859110
    Abstract: An organic light-emitting diode comprising at least one cyclic phosphazene compound, a light-emitting layer formed from at least one matrix material and at least one emitter material, wherein the at least one matrix material comprises at least one cyclic phosphazene compound, the use of cyclic phosphazene compounds in organic light-emitting diodes and a device selected from the group consisting of stationary visual display units, mobile visual display units and illumination units comprising at least one inventive organic light-emitting diode, and selected cyclic phosphazene compounds and processes for preparing them.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: October 14, 2014
    Assignees: BASF SE, Koninklijke Philips Electronics N.V., Osram Opto Semiconductors GmbH, Siemens Aktiengesellschaft
    Inventors: Evelyn Fuchs, Oliver Molt, Nicolle Langer, Christian Lennartz, Peter Strohriegl, Pamela Schroegel, Herbert Friedrich Boerner, Volker Van Elsbergen, Arvid Hunze, Ralf Krause, Guenter Schmid
  • Patent number: 8846922
    Abstract: The present invention relates to functionalized fluoroalkylfluorophosphate salts, in particular as ionic liquids, to the preparation thereof and to the use thereof.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: September 30, 2014
    Assignee: Merck Patent GmbH
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai Mykola Ignatyev, Michael Schulte, Wolfgang Hierse, Waldemar Wiebe, Helge Willner
  • Patent number: 8829188
    Abstract: The invention relates to fluoroalkylfluorophosphorane adducts and the use thereof for masking OH groups in organic compounds.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: September 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai (Mykola) Ignatyev, Michael Schulte
  • Publication number: 20140199600
    Abstract: The present invention provides a nonaqueous electrolyte solution, which can improve flame retardancy and ameliorate performances of a battery without deteriorating the basic battery performance as far as possible, and a secondary battery. The nonaqueous electrolyte solution is a nonaqueous electrolyte solution for a secondary battery that contains metal salts including ions of metals belonging to group 1 or 2 of the periodic table and a specific cyclic compound having phosphorus and nitrogen atoms in a non-protonic solvent. The non-protonic solvent is a solvent that contains at least one kind of carboxylic acid ester compound and carbonic acid ester compound, and a ratio (MPN/Ms) between a mass (Ms) of the non-protonic solvent containing the metal salts and a mass (MPN) of the cyclic compound is 0.01 to 1.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: FUJIFILM CORPORATION
    Inventors: Toshihiko YAWATA, Ikuo KINOSHITA
  • Patent number: 8778512
    Abstract: The present invention relates new compounds and to an organic electronic device comprising at least one substantially organic layer comprising a non fully conjugated chemical compound, which compound is preferably used in electron transport layers, electron injection layers. The invention also includes a process for preparing an organic electronic device, wherein the substantially organic layer comprising a non fully conjugated chemical compound is deposited on a first layer, and a second layer is deposited on the substantially organic layer, preferably a cathode being deposited on the substantially organic layer comprising the non fully conjugated chemical compound.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: July 15, 2014
    Assignee: Novaled AG
    Inventors: Sascha Dorok, Ulrich Heggemann, Andrea Lux, Carsten Rothe
  • Patent number: 8779133
    Abstract: Provided are novel ligands for transition metal complexes which exhibit high coordination power with respect to metals by being free of substituents at the positions ortho to phosphorus or arsenic and which have electron-withdrawing power comparable to the highest level known in conventional ligands. One ligand includes a compound represented by General Formula (1): R1R2R3A or General Formula (2): R1R2A-Y-AR3R4 and having a total of 15 to 110 carbon atoms. In the formulae, A is phosphorus or arsenic; R1, R2, R3 and R4 are each independently a substituted pyridyl group having optionally different electron-withdrawing groups bonded to the positions meta to the atom A as well as hydrogen atoms bonded to the positions ortho to the atom A; and Y is a divalent group derived from a C2-20, optionally substituted and optionally heteroatom-containing, aliphatic, alicyclic or aromatic compound or from ferrocene.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: July 15, 2014
    Assignee: National University Corporation Okayama University
    Inventors: Toshinobu Korenaga, Takashi Sakai, Aram Ko
  • Patent number: 8722208
    Abstract: Disclosed is an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of high driving stability, and of a simple structure. The organic EL device is constituted of an anode, organic layers containing a phosphorescent light-emitting layer, and a cathode piled one upon another on a substrate and a phosphine oxide derivative represented by general formula (1) is contained in a phosphorescent light-emitting layer, an electron-transporting layer, a hole-blocking layer, or an exciton-blocking layer. In general formula (1), L1 is a direct bond or an aromatic group with a valence of 1-3 and Ar1 is an aromatic group. The two Ar1 groups linked to the same nitrogen atom may form a nitrogen heterocycle and may further form a fused ring together with the said nitrogen heterocycle.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: May 13, 2014
    Assignee: Nippon Steel & Sumikin Chemical Co., Ltd.
    Inventors: Takahiro Kai, Hideki Tanaka, Mitsuru Suda, Toshihiro Yamamoto, Megumi Matsumoto
  • Publication number: 20130331576
    Abstract: The invention provides novel ligands for transition metal complexes which exhibit high coordination power with respect to metals by being free of substituents at the positions ortho to phosphorus or arsenic and which have electron-withdrawing power comparable to the highest level known in conventional ligands. A ligand of the invention includes a compound represented by General Formula (1): R1R2R3A or General Formula (2): R1R2A-Y-AR3R4 and having a total of 15 to 110 carbon atoms. In the formulae, A is phosphorus or arsenic; R1, R2, R3 and R4 are each independently a substituted pyridyl group having optionally different electron-withdrawing groups bonded to the positions meta to the atom A as well as hydrogen atoms bonded to the positions ortho to the atom A; and Y is a divalent group derived from a C2-20, optionally substituted and optionally heteroatom-containing, aliphatic, alicyclic or aromatic compound or from ferrocene.
    Type: Application
    Filed: February 16, 2012
    Publication date: December 12, 2013
    Applicant: National University Corporation Okayama University
    Inventors: Toshinobu Korenaga, Takashi Sakai, Aram Ko
  • Publication number: 20130303767
    Abstract: A process for transforming a group >C?O (I) in a compound into a group >C?S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P2S5.2 C5H5N as a thionating agent. A thionating agent which is crystalline P2S5.2 C5H5N.
    Type: Application
    Filed: July 8, 2013
    Publication date: November 14, 2013
    Inventors: Birgitta PETTERSSON, Vedran HASIMBEGOVIC, Per H SVENSSON, Jan BERGMAN
  • Patent number: 8546571
    Abstract: A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral catalyst and a source of hydrogen, wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group; and R4 is alkyl or aryl, wherein: the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; and the term halogen means fluorine, chlorine, bromine or iodine.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 1, 2013
    Assignee: BIAL—Portela & C.A., S.A.
    Inventors: David Alexander Learmonth, Antonio Zanotti-Gerosa, Gabriela Alexandra Grasa, Alexander Beliaev
  • Patent number: 8518913
    Abstract: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard I. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8518911
    Abstract: The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: August 27, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason D. Katz, Sandra L. Knowles, James P. Jewell, David L. Sloman, Matthew G. Stanton, Njamkou Noucti
  • Publication number: 20130197228
    Abstract: The present invention relates to functionalised fluoroalkylfluorophosphate salts, in particular as ionic liquids, to the preparation thereof and to the use thereof.
    Type: Application
    Filed: August 30, 2011
    Publication date: August 1, 2013
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai Mykola Ignatyev, Michael Schulte, Wolfgang Hierse, Waldemar Wiebe, Helge Willner
  • Publication number: 20130184461
    Abstract: Mechanosynthesis trajectories are described which are approximately coaxial, and are shown to be useful in a wide range of mechanosynthesis reactions regardless of the nature of the tip or the feedstock being transferred.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 18, 2013
    Inventors: Robert A. Freitas, JR., Ralph C. Merkle
  • Publication number: 20130178627
    Abstract: Methods and systems for building three-dimensional workpieces are described using a plurality of mechanosynthetic reactions. These methods may employ engineered reliability in reactions and process conditions and may use simulated or otherwise vetted reaction sequences, to allow workpieces requiring many reactions to be built with acceptable reliability. These many reactions may be the repetition of one or a small number of reactions, or many diverse reactions, or a combination thereof.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 11, 2013
    Inventors: Robert A. Freitas, JR., Ralph C. Merkle
  • Publication number: 20130178628
    Abstract: The invention relates to fluoroalkylfluorophosphorane adducts and the use thereof for masking OH groups in organic compounds.
    Type: Application
    Filed: August 30, 2011
    Publication date: July 11, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Berthold Theo Hoge, Anne Julia Bader, Nikolai (Mykola) Ignatyev, Michael Schulte
  • Publication number: 20130178626
    Abstract: Processes are described for manufacturing atomically-precise tips using one or more tips in one or more mechanosynthetic reactions to create one or more atomically-precise tips. The processes may employ a variety of feedstock, binding any of a wide range of atoms to a workpiece to build the one or more atomically-precise tips. The processes result in atomically-precise mechanosynthesis tips with a wide variety of possible tip structures using a wide range of feedstock binding elements. Characteristics of such tips that may be used when designing new embodiments are also described.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 11, 2013
    Inventors: Robert A. Freitas, JR., Ralph C. Merkle
  • Publication number: 20130126792
    Abstract: The present invention relates to compounds of the formula (I), to the use of compounds of the formula (I) in electronic devices and electronic devices comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compounds of the formula (I) and to formulations comprising one or more compounds of the formula (I).
    Type: Application
    Filed: July 12, 2011
    Publication date: May 23, 2013
    Applicant: Merck Patent GmbH
    Inventors: Irina Martynova, Adam W. Franz, Christof Pflumm, Amir Hossain Parham, Arne Buesing, Rémi Manouk Anémian, Anja Gerhard
  • Publication number: 20130102774
    Abstract: A process for transforming a group >C?O (I) in a compound into a group >C?S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P2S5.2 C5H5N as a thionating agent. A thionating agent which is crystalline P2S5.2 C5H5N.
    Type: Application
    Filed: February 3, 2012
    Publication date: April 25, 2013
    Applicant: VIRONOVA AB
    Inventors: Birgitta Pettersson, Vedran Hasimbegovic, Per H Svensson, Jan Bergman
  • Patent number: 8410284
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: April 2, 2013
    Assignees: Merck Sharp & Dohme Corp, Metabasis Therapeutics, Inc.
    Inventors: Qun Dang, Tony S. Gibson, Hongjian Jiang, De Michael Chung, Jianming Bao, Jinlong Jiang, Andy Kassick, Ahmet Kekec, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, David Wilson, Dariusz Wodka, Brett C. Bookser
  • Patent number: 8377965
    Abstract: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: February 19, 2013
    Assignee: Theravance, Inc.
    Inventors: Sabine Axt, Timothy J. Church
  • Patent number: 8338701
    Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: December 25, 2012
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
  • Patent number: 8338700
    Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the otherside of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: December 25, 2012
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
  • Patent number: 8288545
    Abstract: This invention features bis-amides of pyrophosphoric acid and bisphosphonic acids, their preparation, and their use in synthesis of P1,P4-dinucleoside tetraphosphates, tetraphosphonates, and related compounds.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: October 16, 2012
    Assignee: GLSynthesis Inc.
    Inventors: Ivan Yanachkov, George E. Wright
  • Patent number: 8288416
    Abstract: The present invention relates to oxazolidinones of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof. The invention also relates to processes for the preparation of the compound of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof, and to pharmaceutical compositions containing the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof and to methods for treating or preventing microbial infections using the compounds of Formula I and pharmaceutically acceptable salts, pharmaceutically acceptable solvates or polymorphs thereof.
    Type: Grant
    Filed: September 22, 2007
    Date of Patent: October 16, 2012
    Assignee: Wockhardt Ltd.
    Inventors: Vijaykumar Jadgishwar Patil, Mahesh Vithalbhai Patel, Bharat Kalidas Trivedi, Deepak Vijaykumar Dekhane, Mohammad Usman Shaikh, Yati Chugh, Rajesh Prabhakar Chavan, Mohammad Alam Jafri
  • Publication number: 20120214999
    Abstract: A metal complex having a pyridylphosphine compound represented by the formula (1) and a Group 10 metal atom of the periodic table.
    Type: Application
    Filed: October 5, 2010
    Publication date: August 23, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Masato Kawamura
  • Publication number: 20120208989
    Abstract: Fluorinated aromatic materials, their synthesis and their use in optoelectronics. In some cases, the fluorinated aromatic materials are perfluoroalkylated aromatic materials that may include perfluoropolyether substituents.
    Type: Application
    Filed: August 20, 2010
    Publication date: August 16, 2012
    Applicant: THE UNIVERSITY OF SOUTH DAKOTA
    Inventor: Haoran Sun
  • Patent number: 8242137
    Abstract: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: August 14, 2012
    Assignee: Theravance, Inc.
    Inventors: Sabine Axt, Timothy J. Church
  • Patent number: 8212039
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: July 3, 2012
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Michael J. Hawkins, Eugene Powell
  • Patent number: 8207338
    Abstract: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 26, 2012
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Michael N. Greco, Harold R. Almond, Jr., Michael J. Hawkins, Eugene Powell
  • Patent number: 8207373
    Abstract: HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, R1 and R2 each represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthio, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisostere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle, each possibly substituted, and B represents an aryl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: June 26, 2012
    Assignee: Anaconda Pharma
    Inventors: Marta Blumenfeld, Delphine Compere, Jean-Michel Gauthier
  • Patent number: 8207147
    Abstract: Compounds of Formula (I), R1-A-V—B—R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: June 26, 2012
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, John King-Underwood, Martin James Procter, Chrystelle Marie Rasamison, Karen Lesley Schofield, Gerard Hugh Thomas
  • Publication number: 20120157413
    Abstract: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 21, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard I. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20120119191
    Abstract: The present invention relates new compounds and to an organic electronic device comprising at least one substantially organic layer comprising a non fully conjugated chemical compound, which compound is preferably used in electron transport layers, electron injection layers. The invention also includes a process for preparing an organic electronic device, wherein the substantially organic layer comprising a non fully conjugated chemical compound is deposited on a first layer, and a second layer is deposited on the substantially organic layer, preferably a cathode being deposited on the substantially organic layer comprising the non fully conjugated chemical compound.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 17, 2012
    Applicant: NOVALED AG
    Inventors: Sascha Dorok, Ulrich Heggemann, Andrea Lux, Carsten Rothe
  • Publication number: 20120115963
    Abstract: A process for the preparation of a polymer nanoparticle by a photoinduced emulsion polymerization includes preparing an emulsion comprising at least one surfactant, a dispersed phase and a continuous phase. The dispersed phase comprises at least one polymerizable monomer and the continuous phase comprises water and at least one photoinitiator. The at least one polymerizable monomer is polymerized by exposing the emulsion to an electromagnetic radiation having a wavelength so as to induce a generation of radicals from the at least one photoinitiator.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 10, 2012
    Applicant: ETH ZUERICH
    Inventors: Hansjoerg Gruetzmacher, Timo Ott
  • Publication number: 20120094958
    Abstract: The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof.
    Type: Application
    Filed: February 26, 2009
    Publication date: April 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Rene Amstutz, Guido Bold, Simona Cotesta, Wolfgang Jahnke, Andreas Marzinzik, Juliane Constanze Desiree Hartwieg, Silvio Ofner, Frédérik Stauffer, Johann Zimmermann
  • Publication number: 20120028926
    Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.
    Type: Application
    Filed: January 26, 2010
    Publication date: February 2, 2012
    Applicant: CYTOCHROMA INC.
    Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
  • Publication number: 20110294758
    Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: May 25, 2011
    Publication date: December 1, 2011
    Applicant: Metabasis Therapeutics, Inc.
    Inventors: Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
  • Publication number: 20110263533
    Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.
    Type: Application
    Filed: October 12, 2009
    Publication date: October 27, 2011
    Inventors: Qun Dang, Tony S. Gibson, Hongjian Jiang, De Michael Chung, Jianming Bao, Jinlong Jiang, Andy Kassick, Ahmet Kekec, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, David Wilson, Dariusz Wodka, Brett C. Bookser